European Biotechs Question Sustainability Of Platform Technologies
Executive Summary
European biotech companies are facing the question of whether they can sustain themselves over the long-term by focusing on a single platform technology, Ernst & Young suggested in its sixth annual report on the European Life Sciences Industry.
You may also be interested in...
Glaxo Strikes Imitrex Needle-Free Drug Delivery Deal With Weston
Glaxo Wellcome will begin clinical trials with sumatriptan delivered via Weston Medical's Intraject needle-free technology in early 2000, with a product launch anticipated for 2003.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011